Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NSE:BIOFILCHEM'
s Days Payable Range Over the Past 10 Years
Min: 88.15 Med: 241.93 Max: 400.7
Current: 377.57
During the past 13 years, Biofil Chemicals & Pharmaceuticals's highest Days Payable was 400.70. The lowest was 88.15. And the median was 241.93.
NSE:BIOFILCHEM's Days Payable is ranked better than 92.34% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:BIOFILCHEM: 377.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals Days Payable Chart
NSE:BIOFILCHEM vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's Days Payable falls into.
Biofil Chemicals & Pharmaceuticals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) has a Days Payable of 234.52 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. This is near median its historical median of 241.93. Over the past decade, Biofil Chemicals & Pharmaceuticals' Days Payable has ranged from 88.15 to 400.70. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #71 out of 927 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Biofil Chemicals & Pharmaceuticals' Days Payable too high?
Biofil Chemicals & Pharmaceuticals' current Days Payable of 234.52 is near median its 10-year median of 241.93. Over the past 10 years, this metric has ranged from a low of 88.15 to a high of 400.70. The Drug Manufacturers industry median Days Payable is 90.38. Biofil Chemicals & Pharmaceuticals' value of 234.52 is 159.5% above this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #71 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #71 out of 927 companies for Days Payable. This places Biofil Chemicals & Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Biofil Chemicals & Pharmaceuticals' value of 234.52 is 159.5% above this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own Days Payable has ranged from 88.15 to 400.70 over the past decade. While the company's 10-year median is 241.93 vs. the industry median of 90.38, Biofil Chemicals & Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current Days Payable of 234.52 is 159.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current Days Payable is 234.52, which is near median its own 10-year median of 241.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.64, compared to a current price of ₹33.88 — trading 18.6% below its estimated fair value. The current Days Payable is 234.52, which is near median its 10-year median of 241.93 and 159.5% above the Drug Manufacturers industry median of 90.38. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM), the current Days Payable is 234.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹33.88 is trading 18.6% below its estimated GF Value™ of ₹41.64.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:BIOFILCHEM:
Days Payable: 234.52 (near median its 10-year median of 241.93)
GF Value™: ₹41.64 vs. price of ₹33.88 (18.6% below fair value)
Industry Position: 159.5% above the Drug Manufacturers median (#71 of 927)
No single metric tells the full story. See the NSE:BIOFILCHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
74GF Score
Get the complete analysis for NSE:BIOFILCHEM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOFILCHEM has been successfully added to your 
